Sugi Predict

Sugi Predict / Compounds / SCHEMBL27890

SCHEMBL27890

SCHEMBL27890

COC(=O)c1cc(F)c(F)cc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ MAPT P10636 2/20 0.43
▸ GAA P10253 2/20 0.43
▸ GLA P06280 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ CASP1 P29466 1/20 0.43
▸ CASP7 P55210 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ PDGFRB P09619 1/20 0.43
▸ FGFR1 P11362 1/20 0.43
▸ PDGFRA P16234 1/20 0.43
▸ FLT1 P17948 1/20 0.43
▸ FGFR3 P22607 1/20 0.43
▸ KDR P35968 1/20 0.43
▸ TDP1 Q9NUW8 2/20 0.42
▸ NOTUM Q6P988 1/20 0.41
▸ CA12 O43570 2/20 0.41
▸ CA1 P00915 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20470613 0.90 PDGFRB (0.42) KDM4EALDH1A1MAPTGAAGLA
SCHEMBL21932887 0.90 PDGFRB (0.42) KDM4EALDH1A1MAPTGAAGLA
SCHEMBL1418414 0.90 PDGFRB (0.42) KDM4EALDH1A1MAPTGAAGLA
SCHEMBL20511627 0.87 CA12 (0.47) KDM4EALDH1A1MAPTGAAGLA
SCHEMBL24746795 0.86 CA12 (0.46) KDM4EALDH1A1MAPTGAAGLA
SCHEMBL30344115 0.86 CA12 (0.46) KDM4EALDH1A1MAPTGAAGLA
SCHEMBL365903 0.86 MAPT (0.41) KDM4EALDH1A1MAPTGAAGLA
SCHEMBL20571340 0.85 SOS1 (0.48) KDM4EALDH1A1MAPTGAAGLA
SCHEMBL24821258 0.85 KDM4E (0.50) KDM4EALDH1A1MAPTGAAGLA
SCHEMBL25155768 0.85 KDM4E (0.51) KDM4EALDH1A1MAPTGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4692092-A1 NOVEL COMPOUNDS WITH MTORC2-INHIBITORY ACTIVITY AND USES THEREOF Aliad Biopharma (KR) 2026-02-11 — — EP disclosed
CN-118812564-A EGFR-targeting proteolytic targeting chimeras, compositions and uses thereof 厦门宝太生物科技股份有限公司 2024-10-22 — — CN disclosed
WO-2024205377-A1 NOVEL COMPOUNDS WITH MTORC2-INHIBITORY ACTIVITY AND USES THEREOF 알리아드바이오파마 주식회사 2024-10-03 — — WO disclosed
CN-116888108-B Novel EGFR degradation agent 上海齐鲁制药研究中心有限公司 2024-04-19 — — CN disclosed
CN-117157298-A Dual-function chimeric heterocyclic compound of interleukin-1 receptor related kinase 4, preparation method, medicinal composition and application thereof 石药集团中奇制药技术（石家庄）有限公司 2023-12-01 — — CN disclosed
CN-116891502-A EGFR degrading agent 上海齐鲁制药研究中心有限公司 2023-10-17 — — CN disclosed
CN-116888108-A Novel EGFR degradation agent 上海齐鲁制药研究中心有限公司 2023-10-13 — — CN disclosed
WO-2023186069-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 石药集团中奇制药技术（石家庄）有限公司 2023-10-05 — — WO disclosed
EP-3957633-A1 A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF Hinova Pharmaceuticals Inc. (CN) 2022-02-23 — — EP disclosed
WO-2020211822-A1 A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF 成都海创药业有限公司 2020-10-22 — — WO disclosed
US-20140200223-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2014-07-17 — — US disclosed
US-8633212-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-01-21 — — US disclosed
US-8633212-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-01-21 — — US disclosed
US-8633212-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-01-21 — — US disclosed
EP-2406240-A2 INHIBITORS OF BETA-SECRETASE Vitae Pharmaceuticals, Inc. (US) 2012-01-18 — — EP disclosed
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2011-03-24 — — US disclosed
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2011-03-24 — — US disclosed
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2011-03-24 — — US disclosed
WO-2010105179-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-09-16 — — WO disclosed
WO-2010105179-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-09-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140200223-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, PSEN1 KDM4E 2509/4885ALDH1A1 2962/4885MAPT 78/4885
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, PSEN1 KDM4E 2509/4885ALDH1A1 2962/4885MAPT 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.